Connect
MJA
MJA

Value of single troponin values in the emergency department for excluding acute myocardial infarction in Aboriginal and Torres Strait Islander people

Jaimi H Greenslade, Sara Berndt, Laura Stephensen, Katrina Starmer, Greg Starmer, William Parsonage, Victor Lau, Tileah Drahm‐Butler, Tania Davis, Virginia Campbell, Richard Stone, Robert Bonnin, Sarah Ashover, Tanya Milburn, Elizabeth Mowatt, Karlie Proctor, Anthony Brazzale and Louise Ann Cullen
Med J Aust 2022; 217 (1): 48-49. || doi: 10.5694/mja2.51544
Published online: 13 June 2022

Patients with single high sensitivity cardiac troponin I (hs‐cTnI) measurements below specified threshold values are deemed to be at low risk of acute myocardial infarction (AMI).1,2,3,4,5 The accuracy of single hs‐cTnI measurements has not been investigated in Aboriginal and Torres Strait Islander people. The National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand guidelines note that Aboriginal and Torres Strait Islander patients should generally not be treated as being at low risk.6

We evaluated the accuracy of single hs‐cTnI measurements for excluding AMI in Aboriginals and Torres Strait Islanders in a planned analysis of data collected during the observational IMPACT study, which examined the assessment of potential acute coronary syndrome (ACS) in this population. We collected data for adults (18 years or older) who visited the Cairns Hospital emergency department during the 2019 calendar year and were evaluated for ACS. Patients were recruited consecutively on weekdays (8 am – 5 pm). Further details, including on cultural safety, are included in the . The Far North Queensland Human Research Ethics Committee approved the study (HREC/17/QCH/42–1139).

All participants received standard care, including electrocardiography and hs‐cTnI assessments at presentation and 2–3 hours later (hs‐cTn I assay [Beckman Coulter]; limit of detection, 2.3 ng/L), as well as appropriate imaging for coronary artery disease. Thirty days later, research nurses followed up patients by telephone and reviewed medical records for cardiac events, cardiac investigations, and contact with health care providers. The primary endpoint was index type 1 myocardial infarction (T1MI), including non‐ST‐elevation myocardial infarction (NSTEMI), or cardiac death prior to discharge. Secondary outcomes were index AMI (types 1 and 2 MI), and 30‐day major adverse cardiac events (MACE: T1MI, revascularisation, cardiovascular death within 30 days of presentation). Test sensitivity and negative predictive value (NPV) were calculated with exact binomial 95% confidence intervals (CIs), for each hs‐cTnI value below the 99th percentile (18 ng/L).

A total of 110 Aboriginal and Torres Strait Islander people were included in our study (); 58 were men (53%). Fifteen people (14%) had hs‐cTnI values of 2 ng/L or less, none of whom reached the primary or secondary endpoints. Test sensitivity was 100% (95% CI, 93–100%) and the NPV 100% (95% CI, 78–100%) (Box 1). Sensitivity and NPV were also 100% with the cTnI cut‐off recommended by the European Society for Cardiology (4 ng/L);8 this cut‐off excluded AMI for 30 people (27%), none of whom reached the primary or secondary endpoints. Diagnostic accuracy was similar for patients who presented to the emergency department and those who had been transferred from other facilities (data not shown).

Our findings support using single low level hs‐cTnI values to exclude AMI in Aboriginal and Torres Strait Islander people; applying either presentation cut‐off value (2 or 4 ng/L) enabled early exclusion without missing any cases of AMI or MACE. Large proportions of participants reported risk factors for cardiovascular disease, including smoking (66%), diabetes (48%), hypertension (56%), and family history of coronary artery disease (57%) (Box 2). A low hs‐cTnI value may safely exclude AMI, but Aboriginal and Torres Strait Islander people may benefit from referral to culturally appropriate medical services for cardiac risk factor management.

Our study was limited by the small sample size and its restriction to a single centre. Despite 100% sensitivity and NPV, the lower bounds of the 95% CIs with a 2 ng/L cut‐off indicated a considerable degree of uncertainty. Exclusion algorithms should be implemented in the context of the individual’s clinical history. It is unclear how doing so would have affected diagnostic accuracy.

A single low level hs‐cTnI value can be used for early rule‐out of AMI in Aboriginal and Torres Strait Islander patients. Our study advances understanding of ACS assessment by ensuring that our evidence base reflects the diversity of people in our health care system.

 

Box 1 – Receiver operating characteristic curve for using single low level high sensitivity cardiac troponin I values in the emergency department to exclude acute myocardial infarction in Aboriginal and Torres Strait Islander people


Area under the receiver operating characteristic curve = 0.9699.

 

Box 2 – Characteristics of 110 Aboriginal and Torres Strait Islander people who were evaluated for acute coronary syndrome in the Cairns Hospital emergency department during 2019

Characteristic

 


Indigenous status

 

 Aboriginal

91 (83%)

 Torres Strait Islander

15 (14%)

 Aboriginal and Torres Strait Islander

4 (4%)

Age (years), mean (SD)

50.5 (10.9)

 People who experienced index acute myocardial infarction

54.6 (8.8)

 People who did not experience index acute myocardial infarction

46.4 (11.2)

Sex (men)

58 (53%)

Time from symptom onset to presentation (hours), median (IQR)

5.7 (2.5–12.1)

 Presentation within one hour of symptom onset

8 (7%)

Time from presentation to first troponin test (hours), median (IQR)

0.4 (0.3–0.8)

Transfers from other facilities

47 (43%)

Cardiovascular risk factors

 

 Hypertension

62 (56%)

 Dyslipidaemia

50 (46%)

 Diabetes

53 (48%)

 Family history of coronary artery disease

63 (57%)

 Current or recent smoking

72 (66%)

Cardiovascular history

 

 Previous myocardial infarction

31 (28%)

 Previous angina

22 (20%)

 Previous coronary artery bypass graft

10 (9.1%)

 Previous angioplasty

17 (16%)

 Previous stroke or transient ischaemic attack

3 (3%)

 Previous congestive heart failure

6 (6%)

Index acute myocardial infarctions

52 (47%)

 Type 1 during index presentation

50 (46%)

 Type 2 during index presentation

2 (2%)

 Angiography within 30 days

68 (62%)

 Emergency or urgent revascularisation during index presentation

47 (43%)

Outcomes by 30 days

 

 Died

1 (1%)

 Type 1 myocardial infarction

51 (46%)

 Type 2 myocardial infarction

2 (2%)

 Emergency revascularisation

10 (9.1%)

 Major adverse cardiac events

56 (51%)


IQR = interquartile range; SD = standard deviation.

Received 29 November 2021, accepted 19 April 2022

  • Jaimi H Greenslade1,2
  • Sara Berndt3
  • Laura Stephensen1,4
  • Katrina Starmer5
  • Greg Starmer5
  • William Parsonage1,2
  • Victor Lau6
  • Tileah Drahm‐Butler5
  • Tania Davis5
  • Virginia Campbell5
  • Richard Stone5
  • Robert Bonnin5
  • Sarah Ashover3
  • Tanya Milburn3
  • Elizabeth Mowatt5
  • Karlie Proctor5
  • Anthony Brazzale5
  • Louise Ann Cullen1,6

  • 1 Royal Brisbane and Women's Hospital, Brisbane, QLD
  • 2 Australian Centre for Health Services Innovation (AusHSI), University of Technology, Brisbane, QLD
  • 3 Clinical Excellence, Queensland Department of Health, Brisbane, QLD
  • 4 Queensland University of Technology, Brisbane, QLD
  • 5 Cairns Hospital, Cairns, QLD
  • 6 The University of Queensland, Brisbane, QLD


Correspondence: j.greenslade@uq.edu.au

Acknowledgements: 

Jaimi Greenslade is supported by an Advance Queensland Fellowship. Funding for this investigation (data collection and study coordination, health economics analysis, community engagement activities) was provided by the Australian Centre for Health Services Innovation (AusHSI) and the Medical Research Future Fund (MRFF), administered by Brisbane Diamantina Health Partners.

Competing interests:

Louise Ann Cullen has received institutional grants and consulting fees and honoraria from Beckman Coulter and Abbott Diagnostics. These grants were unrelated to the reported investigation.

  • 1. Body R, Mueller C, Giannitsis E, et al; TRAPID‐AMI Investigators. The use of very low concentrations of high‐sensitivity troponin T to rule out acute myocardial infarction using a single blood test. Acad Emerg Med 2016; 23: 1004‐1013.
  • 2. Pickering JW, Than M, Cullen L, et al. Rapid rule‐out of acute myocardial infarction with a single high‐sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta‐analysis. Ann Intern Med 2017; 166: 715‐724.
  • 3. Sandoval Y, Smith SW, Love SA, et al. Single high‐sensitivity cardiac troponin I to rule out acute myocardial infarction. Am J Med 2017; 130: 1076‐1083.
  • 4. Greenslade JH, Cho E, Van Hise C, et al. Evaluating rapid rule‐out of acute myocardial infarction using a high‐sensitivity cardiac troponin I assay at presentation. Clin Chem 2018; 64: 820‐829.
  • 5. Chapman AR, Lee KK, McAllister DA, et al. Association of high‐sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA 2017; 318: 1913‐1924.
  • 6. Chew DP, Scott IA, Cullen L, et al; NHFA/CSANZ ACS Guideline 2016 Executive Working Group. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 2016; 25: 895‐951.
  • 7. Cullen L, Stephensen L, Greenslade J, et al. Emergency department assessment of suspected acute coronary syndrome using the IMPACT pathway in Aboriginal and Torres Strait Islander people. Heart Lung Circ 2022; https://doi.org/10.1016/j.hlc.2022.02.010 [online ahead of print].
  • 8. Roffi M, Patrono C, Collet JP, et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267‐315.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.